65 Million ()

Terns Pharmaceuticals

Lead Left Bookrunner, August 2022

Registered Direct Offering

Terns Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer. Terns’ pipeline includes three clinical stage development programs including a THR- β agonist, an FXR agonist, an allosteric BCR-ABL inhibitor, and a preclinical small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist program.